PEB
05/04/2016 12:05
DIRECTOR
NOT PRICE SENSITIVE
REL: 1205 HRS Pacific Edge Limited
DIRECTOR: PEB: Confirmation of Director Appointment
5 April 2016
CONFIRMATION OF DIRECTOR APPOINTMENT
Pacific Edge Limited (PEB:NZX) has today advised that David Levison's
appointment as a Director has been confirmed, effective as at 2 April 2016.
David is a US-based Director, with an indepth knowledge and experience in the
US healthcare market. He is currently CEO and a Director of CardioDx, a
specialist molecular diagnostic company similar to Pacific Edge.
David is highly respected within the industry and has in market experience in
building a successful medical diagnostics company in the US. His
understanding of commercial molecular diagnostic products in the US
healthcare market, will be of great value to Pacific Edge as it looks to
expand in this region.
David will hold office until Pacific Edge's next Annual Shareholders' Meeting
at which time he will offer himself for election by shareholders. The Board
has determined that David Levison is an Independent Director, for the
purposes of NZX Listing Rule 3.3.2.
ENDS
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
two proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company's
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient's urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.
Refer to www.cxbladder.com for more information.
End CA:00280360 For:PEB Type:DIRECTOR Time:2016-04-05 12:05:30